moder
jame
larrick
md
phd
manag
director
chief
medic
offic
panorama
research
institut
veloc
pharmaceut
develop
mark
alfenito
phd
presid
ceo
engen
bio
inc
workshop
present
nonexhaust
sampl
recent
develop
technolog
approach
acceler
develop
antibodi
drug
clinic
exampl
close
examin
sequenc
physic
properti
antibodi
reach
advanc
stage
develop
like
provid
use
guidelin
novel
antibodi
develop
max
vasquez
adimab
kick
workshop
analysi
antibodi
provid
deep
insight
factor
improv
success
outcom
next
devin
tesar
genentech
describ
effort
engin
molecul
long
vitreal
halfliv
improv
therapi
agerel
macular
degener
major
outcom
work
find
hydrodynam
size
key
contributor
rate
vitreal
clearanc
isol
stabl
highli
product
cell
line
remain
critic
step
develop
larg
scale
manufactur
process
optim
preclin
chines
hamster
ovari
cho
cell
line
develop
cover
bo
yu
larix
bioscienc
big
pharma
small
biotech
increasingli
outsourc
late
stage
develop
manufactur
biolog
success
expens
step
makeorbreak
drug
candid
select
appropri
contract
manufactur
organ
cmo
critic
stephen
chamow
chamow
associ
inc
discuss
process
success
identifi
manag
cmo
help
ensur
success
phase
clinic
studi
cochair
georg
georgiou
univers
texa
austin
jami
scott
simon
fraser
univers
term
immun
repertoir
refer
collect
immunoglobulin
ig
bcell
receptor
tcell
receptor
tcr
produc
b
tlymphocyt
adapt
immun
system
immunereceptor
repertoir
extrem
divers
compris
multipl
cellular
subset
initi
bcell
tcell
subset
gener
bone
marrow
thymu
respect
recombin
germlin
v
j
gene
segment
yield
vdj
recombin
encod
v
domain
complet
ig
heavi
chain
tcr
beta
chain
follow
product
vdj
rearrang
germlin
v
j
gene
segment
recombin
encod
v
domain
ig
light
chain
tcr
alpha
chain
three
mechan
diversif
joint
gene
segment
lend
divers
antigencontact
region
ig
tcr
imprecis
join
addit
n
p
nucleotid
thu
divers
initi
repertoir
produc
combinatori
divers
level
germlin
gene
recombin
combin
heavi
light
alpha
beta
chain
undergo
posit
neg
select
function
b
tcell
repertoir
circul
secondari
lymphoid
tissu
encount
antigen
proper
stimul
antigenbind
clone
activ
divid
differenti
antibodysecret
plasma
cell
memori
b
cell
activ
cell
addit
often
help
cell
b
cell
undergo
isotyp
switch
igm
igd
igg
iga
andor
ige
accumul
somat
hypermut
function
ighv
iglv
gene
region
thu
process
antigen
recognit
antigenactiv
b
cell
becom
clonal
expand
success
round
somat
hypermut
b
cell
also
form
lineag
express
clonal
relat
ig
b
cell
form
heart
adapt
immun
respons
key
understand
health
diseas
develop
therapeut
vaccin
keen
interest
method
character
repertoir
variou
memori
effector
b
tcell
subset
past
year
highthroughput
sequenc
ht
adapt
character
antibodi
tcell
receptor
repertoir
blood
tissu
peopl
anim
briefli
mrna
b
cell
convert
cdna
recombin
v
j
region
pcr
amplifi
sequenc
use
either
primer
specif
entir
set
germlin
gene
race
cover
end
v
region
constantregionspecif
primer
cover
produc
ten
hundredsofthousand
sequenc
b
tcell
clonal
expans
deduc
analysi
sequenc
bcell
clonal
lineag
deduc
somat
mutat
pattern
close
relat
clone
analysi
b
tcell
repertoir
deriv
differ
cellular
compart
eg
blood
vs
solid
tissu
reflect
clonal
migrat
wherea
repertoir
analysi
differ
cellular
subset
reflect
pathway
clonal
differenti
yet
view
amaz
insight
immun
repertoir
analys
provid
signific
bioinformat
challeng
take
analys
next
level
biolog
integr
session
focus
challeng
pose
integr
immun
repertoir
data
largescal
complex
biolog
data
session
cochair
georg
georgiou
describ
approach
quantifi
individu
antibodi
compris
serum
antibodi
respons
combin
ht
recombin
ig
gene
antigenspecif
b
cell
massspectrometr
analysi
peptid
fragment
gener
antigenspecif
ig
blood
exampl
deep
analys
serum
antibodi
elicit
vaccin
pathogen
cell
describ
brandon
dekoski
vaccin
research
center
nih
follow
use
pair
vhvl
read
technolog
develop
sequenti
vaccin
reiter
ontogeni
neutral
antibodi
develop
class
hivspecif
antibodi
daniel
emerl
atreca
inc
report
clinicallevel
studi
immun
repertoir
base
sequenc
analysi
two
chain
antibodi
one
exampl
involv
patient
vaccin
trial
igrepertoir
analys
bcell
plasmablast
inform
vaccin
strategi
ludvig
sollid
univers
oslo
work
role
b
tcell
antigen
celiac
diseas
describ
interact
antibodi
tcr
repertoir
along
role
proteolyt
product
autoantigen
gluten
drive
diseas
jake
glanvil
stanford
univers
develop
method
deduc
antigen
specif
b
tcell
receptor
highthroughput
sequenc
data
would
provid
comput
approach
identifi
b
tcell
clone
involv
immunolog
process
includ
absenc
knowledg
etiolog
agent
johanna
olweu
oslo
univers
hospit
describ
approach
use
tcrrepertoir
data
deriv
healthi
individu
discov
tcr
recogn
cancer
neoantigen
provid
way
discov
cancerspecif
tcr
implant
autolog
cell
expand
activ
specif
attack
patient
tumor
cell
present
provid
excel
exampl
burgeon
systemsbiolog
approach
current
develop
big
data
character
differ
complex
biolog
process
integr
reveal
import
new
insight
discoveri
chairmen
denni
r
burton
professor
chairman
depart
immunolog
microbi
scienc
scripp
research
institut
la
jolla
ca
paul
whi
parren
senior
vice
presid
scientif
director
genmab
utrecht
netherland
professor
depart
immunohematolog
blood
transfus
leiden
univers
medic
center
leiden
netherland
antibodi
natur
evolv
work
togeth
protect
polyclon
antibodi
respons
pathogen
typic
consist
complex
mixtur
antibodi
direct
distinct
diseaserel
target
epitop
antibodi
mixtur
therebi
provid
abil
target
diseas
heterogen
plastic
prevent
escap
strikingli
approv
passiv
immunotherapi
approach
ie
base
administ
purifi
recombin
antibodi
defin
specif
still
develop
monotherapi
search
potent
effect
treatment
therefor
make
lot
sens
investig
educ
assembl
antibodi
combin
bispecif
design
polyclon
prepar
addit
widen
target
bind
antibodymedi
effector
function
effect
antibodi
work
close
concert
session
report
new
insight
select
design
bi
multispecif
antibodi
therapeut
investig
implic
mechan
action
product
session
start
david
corti
humab
biom
discuss
knowledgebas
select
antibodi
specif
therapeut
format
develop
optim
combin
antibacteri
antivir
antibodi
therapi
infecti
diseas
gari
kobing
laval
discuss
novel
experiment
antibodi
therapi
vaccin
treatment
ebola
viru
infect
insight
obtain
emerg
compassion
use
jinanjiao
sab
biotherapeut
detail
develop
transchromosom
cow
abil
rapidli
produc
human
polyclon
antibodi
treatment
emerg
infecti
diseas
result
infect
zika
viru
merscov
break
guanbo
wang
nanj
normal
univers
dive
molecular
mechan
igg
antibodi
connect
activ
complement
therebi
provid
insight
antibodi
might
improv
enhanc
cooper
effector
activ
jeffrey
kearn
merrimack
pharmaceut
demonstr
comput
modelguid
select
led
design
develop
polyclon
prepar
consist
three
antiepiderm
growth
factor
receptor
egfr
antibodi
surpass
individu
compon
term
activ
mechan
joost
neijssen
genmab
final
discuss
intricaci
select
optim
antiegfr
anticmet
antibodi
bind
arm
bispecif
antibodi
activ
bispecif
antibodi
duobodi
heterogen
tumor
contain
egfr
mutat
andor
cmet
pathway
preclin
model
address
inform
select
antibodi
combo
design
bispecif
polyclon
antibodi
repres
strong
growth
area
therapeut
antibodi
field
enorm
potenti
develop
antibodi
therapeut
increas
potenc
breadth
session
cochair
cynthia
lemer
ann
romney
center
neurolog
diseas
brigham
woman
hospit
harvard
medic
school
ann
messer
neural
stem
cell
institut
regen
research
foundat
jame
huston
huston
bioconsult
llc
research
increasingli
focus
find
treatment
neurodegen
diseas
becom
clear
common
involv
misfold
protein
aggreg
accumul
given
way
signific
differenti
molecular
properti
aggreg
protein
session
highlight
led
creativ
scientist
exploit
divers
antibodi
target
protein
underli
neurodegen
diseas
patholog
antibodi
detoxifi
speci
vehicl
vaccin
action
ann
messer
univers
albani
regen
research
foundat
describ
lab
success
intracellular
proteosom
target
intrabodi
bound
promot
activ
degrad
aggreg
protein
huntington
diseas
hd
parkinson
diseas
pd
dramat
clearanc
intracellular
aggreg
diseas
model
investig
scfv
intrabodi
therapi
neurolog
diseas
first
conduct
intrabodi
treatment
neurolog
diseas
use
mous
model
huntington
diseas
hd
pioneer
work
extend
pd
target
alphasynuclein
emphasi
challeng
nac
region
target
situ
vivo
studi
diseas
shown
promis
therapeut
candid
mike
sierk
arizona
state
univers
discuss
recent
experi
treatment
pd
scfv
target
oligom
deliv
use
fusion
protein
pass
target
prof
sierk
chemic
antibodi
engin
long
commit
develop
treatment
hd
pd
alzheim
diseas
group
first
select
scfv
antibodi
target
distinct
conform
pd
neurodegener
protein
use
phage
librari
select
atom
forc
reagent
show
potenti
therapeut
eliez
masliah
uc
san
diego
discuss
research
therapeut
approach
pd
pd
dementia
dementia
lewi
bodi
atrophi
multipl
system
atrophi
relat
neurodegen
diseas
caus
abnorm
accumul
aggreg
brain
second
common
caus
neurodegener
ad
elderli
collabor
recent
develop
transgen
mous
neuron
model
pd
recapitul
induct
human
fibril
recent
research
devot
noninvas
live
cell
imag
aggreg
retina
mice
genet
modifi
express
fusion
protein
demonstr
singlechain
antibodi
reduct
accumul
ad
clinic
trial
exploit
activ
passiv
vaccin
focus
fulllength
earli
result
suffici
posit
justifi
product
develop
although
earlystag
trial
continu
charl
g
glabe
uc
irvin
discuss
investig
structur
differ
differ
form
protein
understand
speci
shown
essenti
precis
form
solubl
insolubl
effect
target
specif
antibodi
progress
ad
offer
import
opportun
ad
cynthia
lemer
brigham
women
hospit
harvard
medic
school
describ
research
candid
target
plaqu
appear
major
contributor
plaqu
format
aggreg
toxic
form
ntermin
truncat
first
two
amino
acid
follow
cycliz
glutaminyl
cyclas
result
hydrophob
degradationresist
pathogen
form
lemer
group
one
earliest
explor
use
immunotherapeut
target
present
evid
recent
investig
reinforc
potenti
passiv
immun
may
offer
import
avenu
ad
prevent
therapi
colleagu
harvard
medic
school
recent
describ
strike
result
implic
microglia
complement
earli
synaps
loss
age
tim
west
diagnost
discuss
develop
human
antibodi
recogn
aggreg
extracellular
form
tau
thought
respons
pathogen
tau
seed
nerv
cell
neurodegen
diseas
includ
progress
supranuclear
palsi
psp
ad
tau
intracellular
microtubuleassoci
protein
phosphoryl
form
aggreg
appear
spread
neuron
neuron
eventu
result
format
neurofibrillari
tangl
within
brain
immunotherapi
requir
uptak
antibodi
neuron
therefor
repres
novel
potenti
critic
approach
suppress
tau
patholog
tauopathi
antitau
antibodi
program
support
abbvi
trial
underway
treatment
psp
chairman
mark
alfenito
phd
presid
ceo
engen
bio
inc
vaccin
activ
antibodi
passiv
tradit
look
agent
prophylaxi
therapi
respect
learn
increasingli
difficult
keep
tradit
separ
field
eg
oncolog
inflamm
immunolog
cleanli
pars
thought
understand
process
integr
within
cell
wholeorgan
basi
learn
field
ever
intersect
overlap
antibodi
immunotherapi
vaccinolog
year
first
time
confer
histori
introduc
talk
session
vaccinolog
end
session
predominantli
devot
diseas
scenario
preexist
therapeut
antibodi
vaccin
develop
direct
target
advantag
vaccin
antibodi
discuss
casebycas
basi
one
exampl
proprotein
convertas
subtilisinkexin
type
target
sever
antihypercholesterolemia
monoclon
antibodi
latestag
clinic
develop
bryce
chackerian
univers
new
mexico
school
medicin
talk
potenti
clinic
financi
advantag
develop
vaccin
target
indic
similarli
yane
morera
center
genet
engin
biotechnolog
cuba
discuss
develop
establish
monoclon
antibodi
cancer
target
vascular
endotheli
growth
factor
vegf
vaccin
kai
xu
univers
maryland
school
medicin
discuss
develop
vaccin
treatment
prevent
heart
failur
novel
exampl
combin
activepass
immunotherapi
strategi
involv
develop
respiratori
syncyti
viru
rsv
vaccin
administr
rsv
vaccin
infant
unsuccess
due
immatur
immun
system
henc
antibodi
therapyprevent
treatment
rout
gregori
glenn
novavax
discuss
develop
rsv
vaccin
use
new
mother
pass
along
passiv
immunotherapi
nurs
babi
yet
approv
sever
antibodi
develop
treat
zika
viru
harri
kleanthou
sanofi
pasteur
discuss
effort
develop
zika
viru
vaccin
final
matthew
macauley
scripp
research
institut
discuss
opposit
end
vaccin
toler
develop
novel
glycan
ligand
antigen
nanoparticl
platform
toler
immun
system
effort
mitig
immun
recognit
therapeut
protein
chairwoman
trudi
veldman
phd
senior
director
biolog
abbvi
session
start
continu
morn
session
antibodi
neurodegen
diseas
present
lili
huang
abbvi
novel
target
multipl
sclerosi
share
data
show
repuls
guidanc
molecul
rgma
exhibit
potent
inhibit
axon
regener
remyelin
inhibit
neutral
antibodi
rgma
earli
clinic
develop
healthi
volunt
multipl
sclerosi
patient
current
underway
major
challeng
biolog
specif
target
neurodegen
diseas
requir
cross
blood
brain
barrier
order
gain
effect
entri
central
nervou
system
engag
target
uli
brinkmann
roch
describ
specif
antibodi
target
deliveri
across
cell
tissu
includ
new
transbloodbrainbarri
deliveri
approach
releas
function
next
two
talk
cover
differ
approach
potenti
treatment
type
degen
diseas
huntington
diseas
ischem
heart
diseas
oskar
smrzka
affiri
ag
discuss
hypothesi
intracellular
mutant
huntingtin
protein
htt
present
put
extracellular
compart
target
antibodi
data
present
show
certain
protein
domain
success
target
provid
mutant
htt
lower
plasma
organ
combin
phenotyp
benefit
ke
cheng
uncchapel
hill
set
specif
target
circul
stem
cell
engag
injur
cardiomyocyt
endotheli
cell
ischem
tissu
use
bispecif
antibodi
target
stem
cell
also
coloc
platelet
macrophag
natur
target
injuri
site
creat
regen
cell
coaggreg
final
two
present
cover
applic
antibodi
nanobodi
manag
hemostasi
inflamm
thoma
mikita
pfizer
describ
gener
high
affin
factor
xiaspecif
igg
potenti
treatment
thrombot
diseas
address
potenti
safeti
concern
potent
revers
agent
antibodi
creat
well
friedrich
kochnolt
univers
medic
center
hamburg
germani
present
gener
character
nanobodi
block
gate
ion
channel
amelior
experiment
glomerulonephr
contact
dermat
anim
model
chairman
jame
larrick
md
phd
manag
director
chief
medic
offic
panorama
research
institut
veloc
pharmaceut
develop
manag
cancer
dramat
chang
past
decad
introduct
novel
immunotherapi
chief
among
inhibitor
checkpoint
receptor
molecul
whose
function
restrain
host
immun
respons
antibodi
inhibit
shown
remark
clinic
benefit
field
evolv
rapidli
mani
clinic
trial
test
novel
checkpoint
inhibitor
eg
alon
combin
target
therapi
sampl
novel
approach
cover
symposium
cell
copotenti
new
concept
recent
appli
enhanc
immun
respons
tumorassoci
antigen
taa
synerg
checkpoint
blockad
adoptivetransf
immunotherapi
mice
diana
gil
page
mayo
clinic
introduc
concept
data
demonstr
monofab
strengthen
antimelanoma
immun
respons
human
mous
model
vivo
next
robert
mabri
jounc
therapeut
describ
progress
agonist
antibodi
target
ico
induc
tcell
costimul
costimulatori
molecul
express
activ
cell
publish
studi
indic
agonist
stimulu
ico
pathway
therapi
result
increas
efficaci
four
five
time
larg
control
treatment
xingx
zhang
albert
einstein
colleg
medicin
provid
updat
new
member
cell
costimulatorycoinhibitori
famili
famili
includ
discov
laboratori
pathway
block
antitumor
activ
previous
activ
tumorreact
cell
howev
mani
patient
respond
antibodi
therapi
possibl
cell
initi
activ
overcom
defici
suzann
ostrandrosenberg
univers
maryland
baltimor
counti
develop
novel
recombin
protein
disrupt
pathway
simultan
activ
tumorreact
cell
detail
fusion
protein
present
ubiquit
immun
checkpoint
receptor
overexpress
cancer
drive
immun
evas
order
bypass
toler
antigen
sink
problem
aris
express
normal
tissu
novimmun
gener
dual
target
bispecif
antibodi
biab
allow
select
blockad
malign
cell
express
mesothelin
krzysztof
masternak
novimmun
describ
work
biab
enhanc
phagocyt
activ
tumor
macrophag
limit
myeloidderiv
suppressor
cell
infiltr
vitro
initi
human
trial
translat
studi
eg
nonhuman
primat
safeti
studi
substanti
reduct
enzymat
activ
potenti
reduc
immunosuppress
adenosin
level
within
tumor
antihuman
antibodi
suppress
two
mechan
direct
inhibit
enzymat
activ
upon
bind
rapid
nearcomplet
intern
describ
bryan
barnhart
bristolmy
squibb
sequenc
antibodi
drive
superior
intern
enhanc
inhibit
anticip
antibodi
technolog
continu
drive
innov
approach
immunooncolog
excit
present
repres
limit
sampl
enorm
work
carri
novel
checkpoint
modul
chairman
andrew
bradburi
research
scientist
group
leader
lo
alamo
nation
laboratori
two
domin
display
platform
yeast
phage
describ
almost
twenti
thirti
year
ago
respect
approach
use
numer
investig
gener
antibodi
clinic
research
util
session
improv
screen
select
approach
cover
well
improv
antibodi
scaffold
suitabl
specif
therapeut
target
andrew
bradburi
lo
alamo
nation
laboratori
discuss
inher
problem
access
divers
present
display
librari
theoret
practic
consider
would
suggest
function
librari
provid
specif
binder
rate
approxim
one
binder
per
ten
million
clone
howev
librari
grown
exponenti
larger
number
isolatedidentifi
binder
increas
correspondingli
compar
divers
binder
obtain
origin
antibodi
genet
materi
screen
phage
display
phage
combin
yeast
display
phageyeast
display
nextgener
sequenc
talk
illustr
divers
isol
binder
depend
upon
screeningselect
method
use
altern
approach
tradit
display
technolog
use
two
hybrid
method
yeast
two
hybrid
antonino
cattaneo
scuola
normal
superior
describ
develop
technolog
select
antibodi
recogn
specif
target
particularli
appli
select
antibodi
specif
posttransl
modif
ptm
involv
anchor
vivo
sitespecif
modif
specif
target
follow
vivo
yeast
select
antibodi
recogn
modif
select
function
antibodi
acetyl
conform
target
describ
one
import
advantag
techniqu
select
antibodi
function
within
cytoplasm
result
addit
abl
inhibit
ptm
activ
select
antibodi
tend
particularli
stabl
b
cell
perfect
display
platform
provid
amplif
simultan
affin
matur
upon
immun
howev
challeng
access
natur
pair
gene
underli
b
cell
respons
target
rodent
yield
hybridoma
rel
easili
case
human
daniel
lightwood
ucb
celltech
describ
approach
isol
memori
b
plasma
cell
repertoir
involv
highthroughput
autom
b
cell
cultur
novel
fluorescencebas
proxim
secret
assay
recent
develop
within
context
droplet
microfluid
approach
appli
immun
anim
human
approach
describ
isol
antibodi
basi
bind
properti
howev
well
known
antibodi
bind
target
similar
activ
henc
desir
screen
antibodi
basi
activ
phenotyp
rather
mere
bind
screen
carri
blind
ie
without
knowledg
target
recogn
new
targetsepitop
may
isol
mikael
mattsson
bioinvent
illustr
case
studi
functionl
discoveri
platform
use
identifi
target
antibodi
improv
activ
compar
standard
chronic
lymphat
leukemia
care
platform
includ
method
differenti
cellbas
pan
primari
cell
highthroughput
function
screen
target
deconvolut
multifunct
antibodi
identifi
use
platform
recogn
possess
intrins
cytotox
activ
block
intern
rituximab
well
boost
immun
effector
cell
function
move
away
biolog
display
platform
jennif
cochran
stanford
univers
describ
novel
microcapillari
screen
approach
interrog
use
number
differ
method
rather
tradit
phenotypegenotyp
linkag
mediat
direct
linkag
protein
encod
dna
platform
isol
individu
cell
minut
capillari
addit
applic
protein
target
display
cell
surfac
approach
also
use
protein
secret
physic
link
cell
produc
furthermor
platform
appli
enzymat
well
bind
activ
final
john
mccafferti
ionta
describ
creation
new
antibodi
form
abl
recogn
inher
difficult
target
base
small
biolog
activ
cysteinerich
peptid
identifi
varieti
plant
toxin
insert
cysteinerich
peptid
antibodi
complementaritydetermin
region
function
peptid
confer
upon
antibodi
simultan
improv
halflif
manufactur
xray
crystallographi
biochem
assay
confirm
peptid
antibodi
correctli
fold
activ
approach
use
gener
antibodi
abl
block
ion
channel
target
tradit
difficult
inhibit
tradit
antibodi
select
method
chairwomen
kerri
chester
professor
molecular
medicin
ucl
cancer
institut
univers
colleg
london
unit
kingdom
janin
schuurman
vice
presid
research
genmab
utrecht
netherland
exploit
exquisit
specif
antibodi
redirect
polyclon
cell
tumor
cell
kill
theme
two
session
engin
antibodi
cell
therapi
session
explor
innov
approach
excit
antibodi
engin
field
fundament
explor
clinic
stage
morn
talk
address
latest
develop
chimer
antigen
receptor
car
approach
cell
typic
redirect
ex
vivo
engin
express
antibodi
bind
domain
fuse
activ
moieti
afternoon
session
center
bispecif
antibodi
approach
redirect
cell
engag
target
cell
kill
session
design
complementari
gener
live
discuss
stimul
new
line
think
first
talk
morn
session
hinrich
abken
univers
cologn
address
challeng
focus
kill
activ
cart
toward
malign
target
cell
encourag
data
present
specif
cart
effect
elimin
lymphoma
cell
attack
posit
hematopoiet
stem
progenitor
cell
next
wayn
marasco
danafarb
cancer
institut
harvard
medic
school
present
excit
result
antibodysecret
cart
cell
manipul
tumor
microenviron
increas
tumor
cell
kill
efficaci
groundbreak
approach
could
address
challeng
solid
tumor
target
cart
cell
dimit
dimitrov
nation
institut
health
explor
mani
antibodi
engin
question
surround
car
format
interrelationship
epitop
locat
antibodi
affinityavid
efficaci
brought
perspect
relat
sever
antibodi
format
includ
cart
network
refresh
break
levi
rupp
cell
design
lab
inc
open
world
intracellular
cart
engin
use
synthet
notch
synnotch
novel
class
engin
receptor
potenti
drive
specifi
program
cell
instanc
enabl
precis
recognit
tumor
cell
excit
util
synnotch
receptor
sens
divers
environment
antigen
drive
local
ration
design
respons
program
lymphocyt
illustr
next
kate
macdonald
centr
drug
research
develop
explor
role
cart
cell
treatment
graftversushost
diseas
gvhd
data
present
alloantigen
cartreg
includ
comparison
cartreg
v
polyclon
treg
vitro
vivo
efficaci
gvhd
prevent
final
talk
david
gilham
celyad
sa
introduc
topic
exploit
natur
killer
cell
receptor
develop
car
approach
nkcart
cell
facilit
interact
multipl
tumor
antigen
potenti
reduc
likelihood
antigenneg
tumor
escap
variant
furthermor
preclin
model
innov
exit
new
approach
suggest
precondit
requir
therapeut
efficaci
chairwomen
janin
schuurman
vice
presid
research
genmab
utrecht
netherland
kerri
chester
professor
molecular
medicin
ucl
cancer
institut
univers
colleg
london
unit
kingdom
afternoon
session
open
comparison
two
major
topic
cover
daylong
session
engin
antibodi
tcell
therapi
bent
jakobsen
immunocor
ltd
adaptimmun
ltd
show
applic
tcell
receptor
tcr
bind
domain
bispecif
adopt
cell
therapi
compar
discuss
therapeut
approach
focus
differ
approach
regard
optim
tcr
biolog
effect
blinatumomab
fragmentbas
bispecif
antibodi
valid
power
bispecif
engag
cell
b
cell
malign
cell
kill
howev
fragmentbas
approach
lead
short
halflif
need
frequent
dose
recent
progress
field
bispecif
technolog
enabl
develop
fulllength
ie
regular
antibodi
architectur
bispecif
antibodi
tcell
recruit
approach
frontrunn
fulllength
bispecif
antibodi
program
present
eric
smith
regeneron
pharmaceut
discuss
advantag
human
fulllength
bispecif
antibodi
next
anoth
full
length
bispecif
antibodi
product
discuss
francoi
gaudet
janssen
vitro
ex
vivo
vivo
data
bispecif
antibodi
current
phase
clinic
studi
acut
myeloid
leukemia
share
discuss
talk
follow
network
refresh
break
mani
valid
clinic
studi
done
cart
cell
involv
target
antigen
bispecif
cart
specif
might
strengthen
clinic
efficaci
overcom
potenti
loss
express
aim
combat
tumor
heterogen
yvonn
chen
univers
california
lo
angel
demonstr
power
bispecif
cart
although
far
session
focus
tcell
therapi
cancer
cell
could
cours
also
use
kill
infecti
diseas
target
guido
ferrari
duke
univers
medic
center
discuss
excit
advantag
use
bispecif
tcell
recruit
antibodi
kill
latent
infect
cell
last
speaker
session
mark
cobbold
massachusett
gener
hospit
cancer
center
present
novel
approach
cell
engag
tumor
cell
kill
abundantli
highli
potent
tumorresid
immun
cell
persist
viral
pathogen
retarget
new
technolog
name
redirect
viral
immunotherapi
chairman
paul
j
carter
senior
director
staff
scientist
antibodi
engin
genentech
common
theme
confer
sinc
incept
present
new
antibodi
engin
technolog
applic
enhanc
clinic
potenti
antibodi
inde
mani
therapeut
antibodi
approv
clinic
develop
engin
improv
exist
function
properti
provid
new
activ
enhanc
develop
characterist
antibodi
technolog
highlight
session
includ
antibodi
fusion
protein
bispecif
antibodi
engin
improv
antibodi
attribut
proteas
resist
antivir
activ
jan
terj
andersen
oslo
univers
present
cytosol
fc
receptor
known
bind
antibodyopson
viral
particl
induc
effici
neutral
inflammatori
signal
antibodi
engin
use
modul
antivir
properti
antibodi
enhanc
therapeut
potenti
william
strohl
janssen
r
describ
antibodyfus
construct
opson
kill
methicillinresist
staphylococcu
aureu
mrsa
antibodi
engin
proteaseresist
evad
inactiv
bacteri
proteas
dario
neri
eth
zurich
discuss
antibodycytokin
fusion
protein
treatment
cancer
chronic
inflamm
design
preclin
clinic
character
antibodycytokin
fusion
protein
present
network
break
peter
roch
glycart
present
novel
ceatarget
tcell
bispecif
antibodi
treatment
solid
tumor
molecul
current
investig
phase
clinic
studi
final
two
talk
session
focu
engin
strategi
facilit
effici
product
bispecif
igg
coexpress
differ
igg
molecul
singl
host
cell
itai
benhar
telaviv
univers
describ
strategi
facilit
correct
heavi
light
pair
use
engin
disulfid
bond
novel
lcmsm
approach
present
precis
assess
chain
pair
nathan
higginsonscott
pfizer
describ
mutat
ration
design
combinatori
screen
promot
effici
assembl
correct
antibodi
heavi
light
pair
paramet
consid
evalu
design
includ
chain
pair
fidel
product
homogen
express
level
develop
characterist
moder
janic
reichert
phd
execut
director
antibodi
societi
editorinchief
mab
manag
director
reichert
biotechnolog
consult
llc
antibodi
societi
nonprofit
associ
repres
individu
organ
involv
antibodi
research
develop
societi
engag
activ
broadli
benefit
member
educ
publish
encourag
collabor
compani
academia
govern
organ
special
session
provid
updat
latestag
antibodi
therapeut
develop
initi
priorit
societi
janic
reichert
antibodi
societi
recapitul
approv
grant
antibodi
therapeut
unit
state
european
union
summar
antibodi
watch
ie
mab
regulatori
review
clinic
studi
due
complet
also
briefli
discuss
societi
initi
address
surround
world
health
organ
intern
nonproprietari
name
system
andrew
bradburi
lo
alamo
nation
laboratori
review
progress
made
societi
initi
address
issu
relat
antibodi
reagent
reproduc
collabor
global
biolog
standard
institut
societi
organ
workshop
research
antibodi
solut
today
tomorrow
held
asilomar
octob
goal
identifi
set
standard
valid
research
antibodi
includ
recommend
adopt
academia
industri
funder
journal
develop
recommend
independ
profici
certif
system
open
access
user
rate
servic
develop
recommend
timelin
followup
plan
introduct
sequenc
recombin
antibodi
research
reagent
dr
bradburi
discuss
outcom
asilomar
meet
futur
plan
initi
societi
support
adapt
immunereceptor
repertoir
airr
commun
develop
recommend
common
repositori
airr
sequenc
data
minim
standard
publish
deposit
airr
sequenc
data
resourc
guidelin
evalu
molecular
statist
method
airr
sequenc
data
discuss
workshop
held
nation
institut
health
fisher
lane
facil
rockvil
md
june
jami
k
scott
simon
fraser
univers
provid
updat
progress
area
discuss
futur
plan
initi
chairwoman
trudi
veldman
phd
senior
director
biolog
abbvi
fc
region
antibodi
contribut
import
biolog
function
antibodydepend
cellmedi
cytotox
adcc
complementdepend
cytotox
cdc
interact
activ
receptor
process
well
known
essenti
contributor
antibodi
efficaci
cancer
indic
recent
becom
appar
interact
inhibitori
also
play
role
present
cluster
antibodi
convey
full
efficaci
sever
agonist
antibodi
target
session
kick
two
present
focus
engag
david
szymkowski
xencor
discuss
engin
fc
domain
optim
affin
select
fc
receptor
present
case
studi
two
antibodi
engin
engag
inhibitori
receptor
current
clinic
trial
allergi
sle
diseas
yuki
iwayanagi
chugai
employ
phdepend
bind
enhanc
cellular
uptak
monomer
multimer
antigenantibodi
complex
vivo
therebi
acceler
solubl
antigen
clearanc
circul
without
compromis
antibodi
halflif
serum
antibodi
halflif
manipul
alter
fc
interact
fcrn
main
featur
therapeut
antibodi
engin
ank
kretzrommel
bird
rock
bio
share
clinic
data
gerilimzumab
antibodi
halflif
day
human
subject
han
de
haard
argenx
describ
clinic
data
antibodi
specif
engag
fcrn
caus
rapid
clearanc
pathogen
antibodi
tumor
necrosi
factor
tnf
inhibitor
antibodi
receptor
fusion
protein
market
decad
approv
mani
indic
field
arthriti
inflammatori
bowel
diseas
ibd
dermatolog
one
would
expect
mechan
action
antitnf
would
similar
indic
would
well
understood
mani
year
research
inhibit
tnf
tnf
inhibitor
current
market
result
efficaci
arthriti
mucos
heal
patient
ibd
observ
antitnf
antibodi
felicia
bloemenda
univers
amsterdam
show
signal
requir
respons
antitnf
ibd
antitnf
induc
regulatori
macrophag
fc
receptor
depend
manner
final
talk
session
david
humphrey
ucb
present
interest
concept
use
care
design
fc
format
control
hexaval
call
fcmultim
tailor
desir
effector
function
manag
potenti
safeti
concern
fcmultim
may
clinic
potenti
recombin
protein
replac
intraven
immunoglobulin
treatment
autoinflammatori
immun
disord
chairman
gregori
p
adam
phd
chief
develop
offic
viventia
bio
year
confer
two
backtoback
session
focus
develop
use
antibodydrug
conjug
adc
fusion
protein
relat
agent
day
highlight
novel
construct
model
better
understand
distribut
agent
preclinicalclin
adc
develop
morn
session
novel
adc
construct
adc
distribut
start
talk
thoma
sandal
crescendo
biolog
describ
conjug
fusion
base
upon
singl
domain
antibodi
fragment
known
humabodi
potenti
benefit
small
humabodi
drug
conjug
hdc
larger
adc
includ
abil
util
plug
play
engin
rapidli
evalu
multipl
format
except
fast
tumor
penetr
low
system
exposur
due
extrem
potent
payload
gener
lack
suscept
multidrug
resist
mechan
immunotoxin
potenti
game
changer
target
payload
field
howev
must
deimmun
order
effect
use
treatment
cancer
ronit
mazor
nation
cancer
institut
discuss
work
use
new
approach
induc
immun
toler
order
develop
immunotoxin
low
immunogen
nick
cox
stanford
univers
describ
work
develop
evalu
drug
conjug
util
extrem
stabl
peptid
disulfidebond
core
known
knottin
knottin
peptidedrug
conjug
kdc
readili
synthes
potenti
increas
tumor
penetr
preclin
result
antiintegrin
kdc
fckdc
fusion
present
two
speaker
describ
work
develop
valid
comput
model
use
predict
bind
distribut
antibodiesadc
tumor
environ
john
rhoden
eli
lilli
present
novel
experiment
valid
conceptualmathemat
model
interact
antibodi
bival
vs
bispecif
cell
surfac
antigen
model
incorpor
critic
properti
includ
structur
flexibl
key
compon
antibodi
target
antigen
bind
epitop
well
antigen
densiti
express
level
antigen
bispecif
antibodi
employ
greg
thurber
univers
michigan
develop
multiscal
model
adc
coupl
system
organlevel
distribut
tissuelevel
distribut
discuss
model
describ
use
understand
distribut
adotrastuzumab
emtansin
mous
xenograft
model
includ
effect
drugantibodi
ratio
result
drug
deconjug
impact
unconjug
antibodi
penetr
adc
tumor
afternoon
session
adc
preclin
clinic
develop
begin
talk
denni
benjamin
seattl
genet
describ
develop
newgener
adc
base
upon
studi
cancer
antigen
target
drug
potenc
mechan
linker
stabil
condit
drug
releas
physicochem
properti
conjug
biodistribut
new
highpot
drug
discuss
carl
uli
bialucha
novarti
describ
discoveri
optim
broad
vivo
function
character
novel
adc
base
multifactori
lead
select
campaign
incorpor
readout
cell
bind
intern
propens
vitro
cytotox
coupl
select
optim
linkerpayload
pair
base
deep
vivo
profil
includ
unbias
highthroughput
studi
panel
unselect
patientderiv
ovarian
xenograft
model
next
talk
alfr
zippeliu
hospit
basel
address
time
combin
adc
treatment
immunooncolog
describ
work
demonstr
specif
adc
particularli
effect
elicit
antitumor
immun
poorli
immunogen
aggress
malign
render
suscept
cancer
immunotherapi
john
lambert
immunogen
describ
develop
adc
use
novel
dnaalkyl
payload
wide
preclin
therapeut
window
present
updat
preclin
earli
clinic
develop
christoph
thano
halozym
therapeut
present
work
develop
evalu
antiegfr
adc
effect
cancer
kra
braf
pathway
mutat
therebi
address
critic
limit
egfr
target
agent
antiegfr
adc
team
develop
bind
effici
egfroverexpress
tumor
exhibit
limit
bind
egfr
healthi
tissu
potenti
increas
potenti
therapeut
window
final
present
session
herren
wu
medimmun
describ
novel
biparatop
adc
bind
two
nonoverlap
epitop
adc
capabl
mediat
greater
degre
payload
deliveri
tumor
cell
effect
tumor
cell
refractori
relaps
treatment
preclin
efficaci
studi
nonhuman
primat
safeti
studi
share
audienc
